Navigation Links
Even the boss doesn't follow the doctor's orders
Date:3/2/2010

ANN ARBOR, Mich.---Only 68 percent of corporate executives took their cholesterol lowering medication as prescribed by a doctor, a new study shows.

Overall, the executives who took their medication even sporadically were twice as likely to meet their cholesterol goals. The study finding also questions the prevailing wisdom that income is a primary factor in medication adherence.

University of Michigan researchers studied 1,607 executive level managers at a major financial institution from 1995 to 2004, said Alyssa Schultz, health science research associate at the U-M School of Kinesiology Health Management Research Center, and one of the study authors.

Researchers wanted to discover the rate of medication adherence, and also what happened to cholesterol levels in executives who did or didn't take statins. Statin drugs lower the low-density lipoprotein (LDL) cholesterol, or the so-called bad cholesterol. Statins are proven effective and are a first-line treatment for lowering cholesterol.

Adherence was defined as taking medication as prescribed at least 80 percent of the time. Overall, statin users were twice as likely to meet the near optimal goal of 130 mg/dL or less, than non-statin users. Among executive who took statins, 70 percent achieved the near-optimal goal and 30 percent achieved the optimal goal of 100 mg/dL or less, compared to 55 percent and 21 percent, respectively, for non-statin users who weren't prescribed the drug

Even executives who took their medication sporadically did much better than the non-statin users, Schultz said. "It seems to show that some medication use is better than none, however adherence is associated with the best outcome of all," she said. The executives who actually did adhere to the statin regimen were significantly more likely to achieve their cholesterol goals than those who took the medication sporadically.

Researchers in this study did not look at reasons why the executives did or didn't follow their doctor's orders, but past research on the topic suggests cost is a factor. However, this study population was predominately white male and more highly educated and compensated than more than the average person.

"Many people think cost is the main reason for medication non-adherence but this doesn't appear true since these people have relatively high salaries," said Schultz.

Using statins could actually save money. Previous research on the effectiveness of statin use in a population at high risk for cardiovascular disease found that a health plan with 210,000 covered lives and 9,336 at-risk employees could yield a $1,735 reduction in costs per treated patient.

So what can employers do? Make sure statins are a covered benefit, said Schultz. Do screening to identify at-risk employees. Partner with health care and pharmacy providers to address reasons for poor medication adherence.


'/>"/>

Contact: Laura Bailey
baileylm@umich.edu
734-764-1552
University of Michigan
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
3. Treating depression may improve recovery of heart rate variability following coronary syndromes
4. Study finds primary care depression treatment often does not follow quality guidelines
5. Grocery Shoppers Are Following Stars to More Nutritious Choices
6. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
7. Methadone and systematic follow-up: the best solution for managing chronic pain
8. Catheter angiography may be an unnecessary follow-up to CT angiography
9. Conseco to Host Follow-Up Long-Term Care Conference Call
10. EPA Says Follow-Up Sampling Shows No PCB Risk at Park Ridge Elementary School
11. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... Many individuals looking to lead a healthy lifestyle have ... IsoPasta by Isolator Fitness has delved into this niche allowing those giving up ... repercussions. IsoPasta has 30 grams of protein and only 7 grams of carbohydrates ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... learn how to start an IV and draw blood, combining technology with traditional ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... According to ... surgeries are beginning to account for a significant portion of hernia repairs throughout the ... of the Beverly Hills Hernia Center notes that this trend has not only been ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television ... a demanding job, and no time to decompress, Rabinowitz found herself drawn to a ... meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with her ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
Breaking Medicine Technology: